Last €191.85 EUR
Change Today -0.80 / -0.42%
Volume 5.7K
As of 11:35 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Open
€193.50
Previous Close
€192.65
Day High
€194.20
Day Low
€190.00
52 Week High
02/25/15 - €198.70
52 Week Low
10/16/14 - €120.00
Market Cap
2.9B
Average Volume 10 Days
6.9K
EPS TTM
€4.71
Shares Outstanding
15.4M
EX-Date
04/10/15
P/E TM
40.7x
Dividend
€1.30
Dividend Yield
0.63%
Current Stock Chart for SARTORIUS STEDIM BIOTECH (DIM)

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides cutting-edge equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions cover fermentation, filtration, purification, fluid management, and lab technologies supporting the biopharmaceutical industry to develop and produce drugs. Its products include single-use filter membranes, single-use and reusable bioreactors, single-use bags, tubing, connectors, containers, and cell culture media. The company also provides filtration systems, filter integrity testing equipment, and sophisticated services, as well as lab consumables, including weighing, quality control, liquid handling, lab water purification, cell cultivation, and filtration/purification products. It serves biopharmaceutical, pharmaceutical, food, and chemical manufacturers; and research and development laboratories. Sartorius Stedim Biotech S.A. was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,600 Employees
Last Reported Date: 10/21/14
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman of The Board and Chief Executive Off...
Total Annual Compensation: €922.0K
Executive Vice President of Operations & IT a...
Total Annual Compensation: €552.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €549.0K
Executive Vice President of Marketing Sales &...
Total Annual Compensation: €568.0K
Compensation as of Fiscal Year 2013.

sartorius stedim biotech (DIM) Key Developments

Sartorius Group Reports Earnings Results for the Year Ended December 31, 2014

Sartorius group reported earnings results for the year ended December 31, 2014. For the period, the company reported sales revenue of EUR 891.2 million against EUR 791.6 million a year ago. Underlying EBITDA was EUR 186.8 million against EUR 162.3 million a year ago. Relevant net profit was EUR 73.7 million against EUR 64.8 million a year ago. Earnings per share was EUR 3.87 against EUR 3.46 a year ago. Capital expenditure was EUR 80.9 million against EUR 60.6 million a year ago. Net debt was EUR 335.6 million against EUR 345.1 million a year ago. EBIT was EUR 126.2 million against EUR 110.0 million a year ago. Profit before tax was EUR 96.3 million against EUR 95.4 million a year ago. Profit after tax from continuing operations was EUR 63.9 million against EUR 66.1 million a year ago.

Sartorius Stedim Biotech S.A. Proposes Dividend for the Fiscal Year 2014

Sartorius Stedim Biotech S.A. resolved to submit a proposal to the annual general shareholders' meeting on April 7, 2015, to pay a dividend of EUR 1.30 per share for fiscal 2014, up from EUR 1.20 a year earlier. The total profit distributed would rise from EUR 18.4 million to EUR 20.0 million.

Sartorius Stedim Biotech S.A. Announces Unaudited Earnings Results for 2014; Provides Earnings Guidance for Full Year of 2015

Sartorius Stedim Biotech S.A. announced unaudited earnings results for 2014. For the period, the company reported sales revenue of EUR 683.5 million against EUR 588.4 million a year ago. EBITDA was EUR 160.5 million against EUR 135.6 million a year ago. Net profit was EUR 87.2 million against EUR 75.2 million a year ago. Underlying EBITDA advanced 18.4% to EUR 160.5 million. Underlying earnings per share were EUR 5.68, up year over year from EUR 4.90. Net debt was reduced by nearly one-third to EUR 87.4 million. For the full year of 2015, the company forecasts sales revenue to increase by about 4% to 7% in constant currencies. Its underlying EBITDA margin is projected to rise to approx. 24.0% to 24.5% in constant currencies. Furthermore, the capex ratio is expected to be in the range of 6% to 8%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €191.85 EUR -0.80

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $24.70 USD +0.10
General Electric Co $25.63 USD -0.235
Pall Corp $101.74 USD -0.75
Thermo Fisher Scientific Inc $128.90 USD -0.83
View Industry Companies
 

Industry Analysis

DIM

Industry Average

Valuation DIM Industry Range
Price/Earnings 37.3x
Price/Sales 4.1x
Price/Book 5.2x
Price/Cash Flow 37.2x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit www.sartorius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.